Revolution’s Rasonque Shows Promise In Lung Cancer
Now approved in pancreatic cancer, Revolution is hoping to extend the use of Rasonque into non-small cell lung cancer, alongside developing its other more mutation-specific RAS inhibitors in the pipeline.
Scrip - September 4, 2026

Menarini Moves into Obesity Market With Gan & Lee Pact
Deal Snapshot: The Italy-headquartered firm is linking up with the Chinese metabolic disease specialist and has bagged the rights in Europe to bofanglutide, a fortnightly injection for weight management.
Scrip - September 4, 2026

Executives On The Move: A New CCO At Oruka As It Looks To Advance Its Novel Skin Therapies
Other executive moves this week include Vivace and Ambros making senior executive changes ahead of Phase III milestones.
Scrip - September 4, 2026

EU Advocate General Says Scrap 80% Cosmetics And Pharma Wastewater Cost Share
An Advocate General has recommended that the European Court of Justice annul the provision requiring medicines and cosmetics producers to fund at least 80% of quaternary wastewater treatment costs, finding that the EU institutions cannot show how they calculated the sector split.
HBW Insight - September 4, 2026

Aspen Targets Broader GLP-1 Growth As Semaglutide Supply Clarity Nears
Aspen expects clarity within weeks on the API issue delaying its Canadian semaglutide, while backing a broader GLP-1 growth opportunity driven by lower prices, higher volumes and emerging-market expansion.
Generics Bulletin - September 4, 2026

EU Legal Opinion Offers Industry Reprieve On UWWTD
A key tenet of the controversial extended producer responsibility scheme that forms part of the EU’s Urban Waste Water Treatment Directive should be annulled, according to an opinion from CJEU advocate general Juliane Kokott that has been celebrated by the pharmaceutical industry.
Generics Bulletin - September 4, 2026

Mineralys CEO Makes The Case For Lorundrostat Ahead Of FDA Verdict
AstraZeneca's Baxfendy approval has opened the door for aldosterone synthase inhibitors in hypertension, and Mineralys's lorundrostat could be the next one through.
Scrip - September 4, 2026

Stryker, Boston Scientific, Medtronic And Zimmer All Want More M&A — But For Different Reasons
Medtech’s largest players are not waiting for conditions to improve before deploying capital — Stryker, Boston Scientific, Medtronic and Zimmer Biomet all signaled accelerating deal activity this earnings season, each with a distinct playbook for what to buy and when.
Medtech Insight - September 4, 2026

FTC Backing Could Open New Antitrust Route For Biosimilars
The FTC has urged the Fourth Circuit to keep acquisitions of pending patent applications within reach of antitrust law in a dispute over Amgen’s Enbrel (etanercept).
Generics Bulletin - September 4, 2026

Positive MASH Data Keep Zydus’s Saroglitazar In The Race Against GLP-1s, Others
Zydus’s novel drug saroglitazar hit the primary endpoint in a Phase IIb trial for MASH but other key data are held back for a reveal at forthcoming liver Congresses. The investigative drug faces hotter competition and a broader MASH pipeline in the US post approval of Novo’s semaglutide.
Scrip - September 4, 2026

China Approves Global-First Nine-Month Prophylactic Antibody For Infant RSV
Trinomab’s global-first long-acting prophylactic antibody provides nine months of protection for newborns and infants entering their first respiratory syncytial virus season. Greater efficacy was seen in those at high risk of infection.
Scrip - September 4, 2026

Doing Less, Better: Inside ARM’s Three-Year Plan For The Cell And Gene Therapy Sector
Janus 2.0 Commits 80% Of the Alliance for Regenerative Medicine's Efforts to Regulators and Payers and Is Explicit About What It Leaves Out. The Harder Question Is Whether ARM Can Deliver.
In Vivo - September 4, 2026

Chinese Firms Start Six Global Phase III Trials With US Sites So Far In 2026
Over the past eight months, multiple Chinese firms including Ascletis, Biokin/SystImmune, Akeso, Lupeng/Newave and Hengrui have progressed late-stage multiregional clinical trial programs that include US sites.
Scrip - September 4, 2026

Cyclical Or Structural? Investors Watching As ‘Critical’ Cough & Cold Season Approaches
After two soft seasons, analysts and investors are watching the approaching cough and cold cycle closely. Jefferies' David Hayes told a recent HBW Insight webinar that the coming winter will test whether the slowdown is cyclical, or more of a structural issue.
HBW Insight - September 4, 2026

Proof Of Concept: How A Charity Bridges Lab And Clinic
Why the gap between lab and clinic isn't a science problem but a coordination one, and how a charity is stepping in to bridge it.
In Vivo - September 4, 2026

From ISH Downclassification To RAPID Exclusion: FDA Maps The Diagnostics Landscape
FDA's in vitro diagnostics chief outlined regulatory advances including a companion diagnostic downclassification and a Dec. 26 COVID EUA deadline at a recent conference, while industry pushed back on IVDs' continued exclusion from RAPID, a new CMS reimbursement pathway for breakthrough devices.
Medtech Insight - September 4, 2026

US FDA, SEC Will Share Information, Not Trade Secrets
Memorandum of understanding allows two agencies to share non-public information in order to improve enforcement and compliance, but agreement maintains FDA’s prohibition on sharing trade secrets.
HBW Insight - September 4, 2026